Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics (NQ: HZNP )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Horizon Therapeutics

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
S&amp;P 500 Futures Slip After Home Depot's Q1 Print: Analyst Says Retest Of October Lows Likely
Via Benzinga
Vodafone, Calliditas Therapeutics, Rumble And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
How Is The Market Feeling About Horizon Therapeutics?
Via Benzinga
Looking At Horizon Therapeutics's Recent Unusual Options Activity
Via Benzinga
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics's Return On Capital Employed Overview
Via Benzinga
Here's How Much You Would Have Made Owning Horizon Therapeutics Stock In The Last 10 Years
Via Benzinga
Merger-Bound Horizon Therapeutics' Q1 Earnings Miss Estimates
Via Benzinga
Horizon Therapeutics: Q1 Earnings Insights
Via Benzinga
Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by U.S. Patient Advocacy Groups
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc (“Horizon”) - Rule 2.12 Announcement
From Horizon Therapeutics plc
Via Business Wire
Why Amgen Stock Was Sickly Today
The company's asset-to-be reported underwhelming first-quarter results. 
Via The Motley Fool
Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results
From Horizon Therapeutics plc
Via Business Wire
A Look Into Horizon Therapeutics' Debt
Via Benzinga
A Look Into Horizon Therapeutics Inc's Price Over Earnings
Via Benzinga
Here's How Much You Would Have Made Owning Horizon Therapeutics Stock In The Last 5 Years
Via Benzinga
A Look Into Horizon Therapeutics' Debt
Via Benzinga
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Ranks First in Patient Centricity and Integrity by Patient Advocacy Groups According to New PatientView Survey
From Horizon Therapeutics plc
Via Business Wire
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Here's How Much $100 Invested In Horizon Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies. 
Via Investor's Business Daily
Horizon Therapeutics plc Announces UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the 2023 American Academy of Neurology (AAN) Annual Meeting
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc and Massachusetts Institute of Technology (MIT) Solve Announce the Launch of the Third Annual Horizon Prize to Inspire Sustainable Solutions for Research and Care in the Rare Disease Community
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces FDA Approval of an Update to the Indication Language for TEPEZZA® (teprotumumab-trbw) to Specify its Use in Thyroid Eye Disease (TED) Patients Regardless of Disease Activity or Duration
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Release First-Quarter 2023 Financial Results on May 3, 2023
From Horizon Therapeutics plc
Via Business Wire
Jeff Bezos, George Soros, Mark Cuban, and Ray Dalio All Have One Thing in Common: They're Making a Big Bet on This Industry
When billionaires jump on the same trend, it’s important for investors to take notice. The pieces often don’t come together immediately, but these investors have millions of dollars in resources... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.